Background and objectives In vivo metabolism of atherogenic apolipoprotein B (apoB)-containing lipoproteins is severely impaired in patients undergoing hemodialysis (HD), resulting in markedly prolonged residence times of these particles. It is unclear whether treatment with statins improves LDL kinetics in HD patients as is known for the general population. Therefore, this kinetic study assessed apoB-containing lipoproteins in these patients.
Introduction
Patients with kidney failure treated with maintenance dialysis are at a particularly increased risk for developing cardiovascular disease (CVD) (1, 2) . The classic cardiovascular risk factor profile, including dyslipoproteinemia, chronic inflammation, and hypertension, does not, however, fully explain the elevated mortality rates. Patients treated with hemodialysis (HD) exhibit an unusual plasma lipoprotein profile, including elevated very-low-density lipoprotein (VLDL) and triglyceride plasma concentrations, because of substantially impaired lipolysis and increased production. Most remarkably, concentrations of total and LDL cholesterol values are usually within normal range (3) .
In a previous in vivo kinetic study using stable isotopelabeling technology, we demonstrated significantly reduced fractional catabolic rates (FCRs) and production rates (PRs) of apolipoprotein B-100 (apoB), the major protein component of LDL, in HD patients compared with healthy controls (4) . As a consequence, these two metabolic defects resulted in normal plasma concentrations but prolonged residence times of circulating LDL particles. Therefore, LDL particles are exposed more extensively to oxidation, which most likely increases atherogenicity. Although most lipoprotein oxidation occurs in the arterial wall, oxidative modification of LDL in plasma cannot be excluded (5) . An experimental study showed that an oxidation product of apoB was significantly correlated with residence time of LDL (6) .
In the general population, therapy with hydroxymethylglutaryl coenzyme A (HMG-CoA) reductase inhibitors (statins), which suppress endogenous cholesterol biosynthesis, improves outcomes in several atherosclerotic diseases (7, 8) . This inhibition consequently leads to upregulation of LDL receptors, resulting in increased clearance and therefore reduced residence time of circulating LDL (9) . In line with this metabolic background, a first retrospective, epidemiologic study in HD and peritoneal dialysis patients showed statin use was associated with a reduction in total and cardiovascular-related mortality (10) .
Whether statins also beneficially influence the kinetics of atherogenic lipoproteins in HD patients is not known. On the basis of our previous studies on lipoprotein kinetics in HD patients, we therefore used stable-isotope technology to examine the in vivo kinetics of apoB-containing particles in six HD patients before and after treatment with atorvastatin. We could demonstrate significantly higher clearance rates and subsequently lower residence times of LDL-apoB after atorvastatin treatment.
Materials and Methods

Study Design
This kinetic study was approved by the Ethics Committee of the Innsbruck Medical University (protocol number UN1922) in adherence with the Declaration of Helsinki, following corresponding protocols previously described and approved by the internal review boards and ethics committees of the Innsbruck Medical University, Austria, and the Jikei University School of Medicine, Tokyo, Japan (4). Informed written consent was obtained from each study participant before study onset and after having taken out liability insurance.
In each case, the kinetic study was performed 1 day after dialysis. For 3 days preceding the investigation, all study participants received a standardized isocaloric diet composed of 30 kcal/kg body weight, 50% carbohydrates, 30% fat, and 20% protein with a maximum of 300 mg cholesterol per day and with no alcohol consumption (4). The participants prepared the diet themselves and were instructed to adhere to their prescribed diet precisely.
After an initial 10-hour overnight fasting period, all study participants maintained their fasting state during the first 12 hours of the study and returned to the isocaloric diet until the last blood drawing. One plastic indwelling catheter was placed intravenously in the nonshunt arm. Sterile, endotoxin-and pyrogen-free trideuterated L-leucine (10 mg/kg body weight, 99% pure; Cambridge Isotopes Laboratories Inc.) was given as a bolus at the beginning of the study. Tracer administration as bolus injection (as opposed to constant infusion) is more convenient for study participants and investigators, has been shown not to disturb steady-state conditions, and is therefore widely used in lipoprotein kinetic studies in humans (11) . Nine-milliliter blood samples were drawn into tubes containing EDTA immediately before tracer administration and 10, 30, 60, 90, 120, 150, and 180 minutes thereafter, followed by hourly blood drawings until 12 hours and at 24, 34 and 48 hours after start of study. EDTA plasma was obtained by low-speed centrifugation and kept on ice until use for lipoprotein separations on the same day. This procedure was repeated after 3 months of therapy with the study medication.
Study Participants
Seven male, stable nondiabetic patients undergoing maintenance HD were initially included in the study between 2005 and 2009 in three Austrian nephrology centers (Innsbruck, Feldkirch, and Salzburg). Inclusion criteria were male sex, HD treatment for .6 months, an age range between 18 and 65 years, and a range of LDL cholesterol plasma concentrations between 90 and 200 mg/dl. Patients with known history of cardiovascular disease, diagnosed diabetes mellitus, familial hyperlipidemia, nephrotic syndrome, use of steroids or immunosuppressive medication, or past use of any lipid-modifying drugs (including statins) were excluded from the study. One patient withdrew consent during the study because of muscle pains presumably caused by atorvastatin and was therefore excluded from the study. All patients except patient 3 were receiving routine erythropoiesis-stimulating agent treatment throughout the study period. Clinical characteristics are given in Table 1 . Dialysis was performed three times weekly for 4 hours on average. Dialysis adequacy was monitored monthly by calculation of Kt/V values.
Study Medication
On the morning after the end of the kinetic study, atorvastatin at a dosage of 10 mg per day was prescribed for 3 months.
Preparation of Lipoproteins and ApoB
VLDL (d,1.006 g/ml), intermediate-density lipoprotein (IDL) (d=1.006-1.019 g/ml), and LDL (d=1.019-1.063 g/ml) were isolated by sequential preparative ultracentrifugation at 10°C from 4 ml of plasma in Quick Seal Tubes using a 50.3 Ti rotor (40.000 rpm, L-70K centrifuge; Beckman Instruments, Palo Alto, CA) (4). Remaining plasma was frozen and kept at 280°C for quantification of apoB.
ApoB was isolated from obtained lipoprotein fractions by isopropanol precipitation as previously described (12) . Briefly, equal volumes of lipoprotein fraction were mixed with 100% isopropanol and incubated for 30 minutes at room temperature on a shaking plate, followed by 30 minutes of centrifugation at 3.500 rpm. Precipitated protein pellets were washed two times with 50% isopropanol, lyophilized, hydrolyzed with 1 ml 6 M HCl for 20 hours at 110°C, and finally dried at 80°C. Norleucine was added as an internal standard. Purity of apoB preparations was checked by SDS-PAGE using 4%-12% NuPage Bis-Tris Gels (LifeTech, Vienna, Austria) under reducing conditions. Under patients' dietary conditions, there was no contribution of other proteins, including apoB48, to the precipitated apoB in VLDL and IDL fractions detected (data not shown).
Determination of Isotopic Enrichment and Kinetic Analysis
Free amino acids were isolated from apoB hydrolysates by cation exchange chromatography (AG-50W-X8, Bio-Rad Laboratories, Richmond, CA) followed by derivatization and determination of tracer/tracee ratios using GCMS as described (4, 13) .
A previously published multicompartment model was built using an interactive computer program (SAAMII, version 1.1; SAAM Institute Inc.) (14) to determine apoB FCRs for VLDL, IDL, and LDL fractions separately ( Figure  1 ) (15, 16) . The PR in mg/kg per day represents the product of FCR and pool size of apoB in lipoprotein fractions assuming a plasma volume of 4.5% of body weight (17) .
Because hematocrit values were not significantly different at the time of the two examinations (Table 2 ) and did not fluctuate during the 48-hour study period (data not shown), this assumption could be implied on all analyses. Individual changes in plasma concentrations of VLDL-, IDL-, and LDL-apoB were within 5% throughout the study period (data not shown), indicating steady-state conditions. Therefore, FCR was assumed to be equal to the fractional synthetic rate. Residence time equals 1/FCR.
Quantification of Apolipoproteins, Lipids, and Routine Laboratory Measures
ApoB concentrations of plasma and lipoprotein fractions thereof were measured by ELISA. An affinitypurified rabbit polyclonal antibody against apoB was used for coating and the same antibody, labeled with horseradish peroxidase, was used for detection. A calibrated standard (Apoproteins Human ApoB, Technoclone, Vienna, Austria) served as a secondary standard (18) . Concentrations of triglycerides, total and HDL cholesterol, urea, creatinine, apoAI, lipoprotein(a), total protein, albumin, glutamate pyruvate transaminase, and C-reactive protein (CRP) were determined with standard assays on a COBAS INTEGRA analyzer (Roche Diagnostics). LDL cholesterol was calculated with the Friedewald formula.
Statistical Analyses
Data are presented as mean 6 SD, as well as median and interquartile range. For statistical comparisons the nonparametric, two-tailed Wilcoxon rank-sum test was used (SPSS, version 20.0, IBM-SPSS software) to compare results before and after treatment with atorvastatin. Significance is defined as P,0.05. Table 1 shows relevant demographic variables, cause of kidney failure, and baseline laboratory measures of the six HD patients studied. Lipids and lipoprotein profiles as well as hematocrit values before and after daily treatment with 10 mg of atorvastatin are summarized in Table 2 . As expected, and in line with previous studies (19, 20) , plasma concentrations of apoB, total, and LDL cholesterol were significantly lower; those of HDL cholesterol, apoAI, triglycerides, lipoprotein(a), and hematocrit were unchanged after statin treatment. Figure 2 illustrates the tracer/tracee ratio curves for apoB-100 from VLDL, IDL, and LDL in HD patients. After 3 months of atorvastatin administration, the mean LDL tracer/tracee ratio curve exhibited a clearly steeper increase, reaching a curve peak at around 10 hours, whereas the baseline investigation led to a peak not before 20 hours. VLDL and IDL curves were similar before and after treatment but differed in peak heights.
Results
Patient Characteristics
Kinetics of ApoB-containing Lipoproteins
Lipoprotein Concentrations, PRs, and FCRs of ApoBcontaining Lipoproteins before and after Treatment with Atorvastatin Table 3 displays plasma concentrations of VLDL-apoB, IDL-apoB, and LDL-apoB, as well as their FCRs and PRs, before and after administration of atorvastatin. FCRs of VLDL-and LDL-apoB were significantly higher after atorvastatin treatment (7.2063.08 versus 5.2062.98 days 21 , P,0.05; 0.85160.772 versus 0.44660.232 days 2 1 , P,0.05), whereas their concentrations were lower compared with baseline. Accordingly, their residence times in plasma-being the inverse values of FCR-were significantly lower (0.14 versus 0.19 day for VLDL and 1.2 versus 2.2 days for LDL). PR was not significantly different. The opposite was observed with IDL-apoB. Its PR was significantly lower, whereas FCRs and concentrations were not significantly different between the two time points.
Discussion
Statin treatment represents the major contemporary drug therapy for atherosclerotic vascular disease. By inhibiting HMG-CoA reductase, the rate-limiting step in cholesterol biosynthesis, statins reduce cholesterol content in hepatocytes and stimulate expression of LDL receptors to finally enhance the removal of atherogenic apolipoprotein B-containing particles from the circulation (21) . As a consequence, statins reduce the residence time of these particles and thus improve the metabolism of the major atherogenic lipoproteins in dyslipidemic patients (9) .
To our knowledge, this is the first study to describe the effects of HMG-CoA reductase inhibition on apoB metabolism in patients undergoing HD. This patient group is also characterized by atherogenic dyslipidemia due to disturbed lipoprotein kinetics (4) . Lower concentrations of VLDL-and LDL-apoB, both accompanied by significantly increased FCRs, were observed in six male HD patients after 3 months of treatment with low-dose atorvastatin. The PR of both proteins was not altered. As a consequence, residence time of these atherogenic particles was also lower. IDL-apoB production, however, was significantly lower, accompanied by a nonsignificant reduction in concentration, while its kinetics was not different. In a stable-isotope study, Pietzsch et al. demonstrated that a prolonged residence time of LDL particles in the circulation leads to increased oxidation in a time-dependent manner (6) . In line with these findings, increased oxidative modification of LDL has been implicated as a cause of accelerated atherosclerosis in chronic renal failure (22, 23) . Increasing FCR without changing PR of atherogenic lipoproteins subsequently leads to decreasing residence times of these particles to values typical for healthy persons. This effect of statin administration might thus reduce particle atherogenicity in HD patients.
The observed differences in kinetic measures of atherogenic lipoproteins represented the prespecified primary endpoint of our study. Any conclusions regarding a clinical significance of these findings, although attractive, must be considered with caution. This is particularly critical because the topic of lipid-lowering medication in HD patients has been extensively discussed for several years.
Two large, prospective, randomized, placebo-controlled trials on statin treatment in HD patients did not show significant benefits in their primary cardiovascular outcome (20, 24) . Their primary endpoints (death of cardiovascular cause, nonfatal myocardial infarction, or nonfatal stroke) remained nearly unchanged. However, a promising risk reduction in the secondary endpoint of "all cardiac events combined" was found in one study (20) .
Recently, another, much larger trial including 9270 patients with kidney failure, the Study of Heart and Renal Protection (SHARP), showed a significant risk reduction in atherosclerotic events in a mixed population of patients with kidney disease; two thirds of the patients had not yet started dialysis and one third were receiving maintenance dialysis (mostly HD) (25) . This protective effect was independent of the stage of kidney disease based on heterogeneity testing (x 2 1 =1.54; P=0.21). However, when the stratum of dialysis patients was analyzed separately, the risk reduction was no longer significant (risk ratio, 0.90; 95% confidence interval, 0.75 to 1.08). Two very recently published meta-analyses concluded that statin therapy prevents atherosclerotic cardiovascular events in patients at all stages of predialysis kidney disease. In dialyzed patients, statins have, in contrast, little or no effect because atherosclerotic events make up a smaller proportion of CVD (26, 27) .
To understand the results from previous randomized controlled trials, the pathophysiology of CVD as well as the basic mechanisms underlying the pathogenesis of dyslipidemia in HD patients must be critically evaluated. In contrast to the general population, in whom obstructive coronary artery disease is the main pathogenic mechanism of CVD, the pathophysiology of CVD in dialysis patients, particularly those undergoing HD, also includes arteriosclerosis, cardiomyopathy, arrhythmia, and heart failure. Accordingly, several additional CVD risk factors, such as oxidative stress, inflammation, insulin resistance, anemia, and disturbances in mineral metabolism, have been proposed in this patient group (28) . In addition, dyslipidemia in HD patients is typically also characterized by elevated plasma concentrations of triglycerides and lipoprotein(a) (29) , as well as decreased circulating concentrations and abnormal composition of HDL leading to a disturbed reversed cholesterol transport pathway, in dialyzed patients (30) . All these markers and pathways contribute substantially to the development of CVD in predialysis and dialyzed patients with kidney failure (3). Because statins have been reported to have no or very little effect on those atherogenic measures, improving the kinetics of apoB-containing lipoproteins as shown in this study might not produce substantial clinical benefits. The observed negative results in the discussed clinical trials of statin therapy might therefore reflect the biomarkers and targets that were chosen to be evaluated but missed several other, not therapeutically influenced targets. Many cardiovascular events not related to atherosclerosis might thus have diluted the potentially beneficial effects of statins. Taken together, our findings shed more light on the complicated interrelation between a disturbed lipoprotein turnover despite normal LDL plasma concentrations, therapy with cholesterol-lowering drugs, and the dismal cardiovascular outcome in these patients. The strength of our study is therefore to demonstrate the normalization of a disturbed lipoprotein pathway by administration of statins to HD patients, who generally do not have atherogenic hypercholesterolemia (the indication for lipid-lowering therapy in the general population).
The major limitation of this study is its small number of patients. However, because of the laborious nature of the experimental work and the limited number of patients with no previous statin treatment, recruiting larger numbers of suitable probands was a severe problem. Fortunately, the effect of atorvastatin treatment on concentrations, FCR, and residence times of LDL-apoB was sufficiently large (resulting in 50% to almost 200% differences; see Table 3 ) to also be observed in our small study group. A further limitation of our study is the lack of a control group with placebo or with no treatment, which could have excluded a time-versustreatment effect. The pronounced effect of statin treatment on kinetic measures argues, however, against a simple time effect. Of note, patient 1, who can be considered a nonresponder to statin treatment (LDL cholesterol decreased from 132 to only 126 mg/dl), also showed no difference in the FCR of LDL-apoB after the treatment period. Finally, we did not adjust for multiple comparisons.
We attempted to keep other influences on the apoB kinetics as small as possible by excluding patients with diabetes mellitus, nephrotic syndrome, or familial hyperlipidemic conditions and patients taking drugs known to influence lipoprotein metabolism. This helped us keep the investigated population as homogeneous as possible and prevent unconsidered confounders from blurring the findings. It thus remains to be shown in future studies whether the findings in our study population can be extrapolated to HD patients with these conditions.
In conclusion, we believe this is the first study to demonstrate a beneficial effect of statin therapy on lipoprotein metabolism in HD patients. Kinetics of atherogenic apoBcontaining lipoproteins were improved after administration of low-dose atorvastatin in HD patients. This may translate into beneficial outcomes, depending on the individual risk profile and the progress of atherosclerotic disease.
